Related Experiment Videos
Prostate cancer associated with CYP17 genotype
M Wadelius1, A O Andersson, J E Johansson
1Department of Medical Sciences, Clinical Pharmacology, University Hospital, Uppsala, Sweden. mia.wadelius@klinfarm.uu.se
Pharmacogenetics
|December 11, 1999
Summary
A specific genetic variation in the CYP17 gene (CYP17A1/A1 genotype) was linked to an increased risk of prostate cancer in Caucasian men. This finding suggests a potential role for this genotype as a susceptibility factor for the disease.
Area of Science:
- Endocrinology
- Genetics
- Oncology
Background:
- Androgens are crucial in prostate cancer development.
- Genetic variations in androgen-regulating genes may influence disease susceptibility.
- The CYP17 gene encodes a key enzyme in testosterone biosynthesis.
Purpose of the Study:
- To investigate the association between a specific polymorphism in the CYP17 gene and prostate cancer risk.
- To determine if CYP17 allelic variations are susceptibility factors for prostate cancer.
Main Methods:
- A population-based case-control study was conducted.
- DNA was extracted from blood samples of 178 prostate cancer patients and 160 age-matched controls.
- Polymerase chain reaction and MspA1I restriction enzyme analysis were used to identify CYP17 gene variants (CYP17A1 and CYP17A2).
Main Results:
- A significantly higher frequency of the CYP17A1/A1 genotype was observed in prostate cancer patients compared to controls (odds ratio 1.61, P=0.04).
- The CYP17A1/A1 genotype is preliminarily reported to elevate circulating androgen levels.
- This genotype may indicate a more active androgen-synthesizing CYP17 enzyme.
Conclusions:
- The CYP17A1/A1 genotype is a potential susceptibility factor for prostate cancer.
- This genetic variation may contribute to prostate cancer risk on a population level.
- Further verification is needed to confirm the role of this genotype in prostate cancer development.